[attention] the third phase of pharma wisdom salon was held as scheduled. Together with Beijing yingkerui and Chongqing dinali, we explored the way of inhalation preparation research and development

In order to strengthen the internal and external cooperation and exchange of Chongqing pharmaceutical industry, improve the level of pharmaceutical R & D and pharmaceutical technology, and promote the development of Chongqing pharmaceutical industry, the theme activity of "gather in 2018 pharmaceutical salon and talk about the development of pharmaceutical industry" will be held in Chongqing one after another under the guidance of Chongqing pharmaceutical industry association, CO sponsored by pharmaceutical intelligence network and pharmaceutical intelligence elite club and supported by pharmaceutical guide The theme activity will be carried out in the form of a series of salons It is estimated that there will be 10 sessions each year (about once a month) Each session will be carried out in different themes For different salon themes, yaozhi.com will invite important figures from the pharmaceutical circle to attend the event to answer questions and solve doubts for the on-site guests At the same time, in addition to the keynote speech, the site gives participants more opportunities to speak and discuss, improve the level of communication, and solve problems Today, the third phase of pharma smart salon sponsored by Pharma smart.com, Pharma smart college and Beijing yingkerui innovative drug research Co., Ltd and supported by the pharmaceutical guide was held in the engineering research center of the Ministry of biological technology education of active substances, Chongqing Normal University The theme of this issue is "Discussion on technology and strategy related to research and development of inhalation preparations" Dr Chen Anping, general manager of Beijing yingkerui, Mr Hu Jie, vice president, Dr Kang Zhiyun, vice general manager, and Dr Wang Laixin, vice president of Chongqing dinali Pharmaceutical Technology Co., Ltd were invited to make theme reports As the first choice of treatment for asthma and chronic obstructive pulmonary disease (COPD), inhalation preparation has been listed as the high-end preparation which is the focus of China's 13th five year plan Under the favorable policy, Beijing yingkerui's Research Center for aerosolized inhalation preparations is listed as the key technology platform of the national "13th five year plan" major special funding, and the center has also built the first domestic technology platform for Chinese medicine aerosolized inhalation preparations, which also makes Beijing yingkerui famous in the field of inhalation preparation research and development In order to let the on-site guests have a more comprehensive and in-depth understanding of Beijing yingkerui, first, Dr Chen Anping introduced the company from three aspects of the company's overview, R & D system and core competitiveness with the theme of "building and introduction of high-end inhalation preparation R & D platform" Combined with the theme and company layout, Dr Chen Anping focused on the research center of aerosolized inhalation preparations and the research center of innovative drugs in the R & D strength section, which also laid the foundation for the next two doctors' speech themes According to reports, the research center of atomized inhalation preparations covers the research and development of traditional Chinese medicine and chemical atomized inhalation preparations, with a technical team of nearly 100 people, and the achievements of the center are gratifying The research projects include 39 traditional Chinese medicine and 26 chemical medicine Among them, 27 research and development projects of atomizing inhalation solution have been signed, with a total cooperation fund of nearly 100 million yuan, 10 authorized patents and 39 patents at the application stage As an important carrier of yingkerui's characteristic innovation road, innovative drug research center is also given high hopes At present, the research and development of innovative drugs are mainly in the fields of anti-cancer, anti-virus, anti-inflammatory pain, asthma and mental illness; more than 30 new drug certificates / production approvals, more than 20 clinical approvals, and more than 200 new drugs have been developed After the on-site guests had a basic understanding of Beijing yingkerui, Mr Hu Jie and Dr Kang Zhiyun started from the research and development of aerosolized inhalations and new drugs respectively, with the title of "research and development status of aerosolized inhalations and progress report on research and development of PCCW aerosolized inhalations" and "Discussion on development mode of innovative drugs" for detailed interpretation Mr Hu Jie mentioned in sharing the current research and development situation of atomized inhalation preparations that up to April 2017, there were about 1000 clinical research reports on atomized inhalation therapy of traditional Chinese medicine, which had good efficacy and very low incidence of adverse reactions However, at present, no atomized preparation of traditional Chinese medicine has been approved for marketing, and the clinical atomized drugs are all over the scope and not standardized, atomization method, atomized dose and indications All of them are not clear and need to be standardized, which also leads to infinite thinking of the guests on site Later, Dr Wang Laixin also brought us the dry goods sharing entitled "key points and case analysis of developing bioanalysis methodology of ultra-low concentration inhaler LC-MS / MS for consistency evaluation" It is reported that his biological analysis service of Chongqing dinali pharmaceutical technology basically covers all drugs on the market, and the core technology includes ultra-low concentration biological sample detection and analysis, nucleic acid drug analysis, dry blood spot quantitative analysis, etc., which has technical advantages in drug analysis of inhalants, ossifying alcohols, tumors, etc Dr Wang Laixin introduced the background of inhaled drugs, difficulties and challenges of inhaled drug methodology, strategies and methods to improve the sensitivity of the methods in detail In addition, combined with three specific cases, including formoterol & budesonide, indarterol & glumonium bromide and tiotropium bromide, he demonstrated the bioanalysis methods of inhaled drugs vividly Finally, he concluded that it is very challenging to achieve low pg / mllloq in bioanalysis, but it is necessary for some drugs such as inhalants; the common sample extraction methods are not enough, so it is necessary to carefully develop and optimize the sample extraction methods; 2-dimensional (2D) chromatography combined with base effect reduction method is worth trying; it is necessary to use the most advanced, sensitive and in the best operation Of course, Dr Wang Laixin also mentioned that the best and most experienced biological analysis scientists are also important At the end of the meeting, as a press axle, Mr Hu Jie shared the R & D achievements of PCRI's aerosol inhalation preparations under the title of "case sharing of aerosol inhalation preparations", including the research on fludostame inhalation solution, the research progress of Yanhuning inhalation solution, the research on carboxymethylstein inhalation solution, the Research on Shuanghuanglian inhalation solution, etc Moreover, Beijing yingkerui has applied for intellectual property rights for the above projects Seeing a vivid case, the guests at the scene were amazed Although inhalation preparations have been listed in the high-end preparations that are the focus of China's 13th five year plan, the development level of inhalation drugs in China is still in the primary stage, the market is monopolized by international pharmaceutical giants, key technologies need to be breakthrough, and inhalation drugs with independent intellectual property rights are urgently needed in clinical practice We believe that with the continuous efforts of companies like Beijing yingkerui and Chongqing dinali pharmaceutical technology, we will welcome more inhaled drugs with independent intellectual property rights in the near future.